Intra-Cellular Poised To Add MDD To Caplyta’s Label

Second Phase III Is Positive

Caplyta succeeded in a second Phase III study as adjunctive therapy for major depression, putting the schizophrenia/bipolar disorder drug on track for sNDA filing later in 2024.

Intra-Cellular will file lumateperone for approval in adjunctive MDD

With a second successful Phase III readout in major depressive disorder this quarter for Caplyta (lumateperone), Intra-Cellular Therapies, Inc. said on 18 June that it intends to seek what would be the drug’s third indication this year, and anticipates approval in the second half of 2025. While Caplyta works toward blockbuster status as a therapy for schizophrenia and bipolar I/II disorder, analysts said an MDD indication should add billions more to its revenue potential.

Key Takeaways
  • Intra-Cellular followed April’s successful Phase III trial of Caplyta in depression with a second trial virtually replicating those results.

CEO Sharon Mates told a same-day call that Intra-Cellular will file a supplemental new drug application with the US Food...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: Organon To Pull Plug On OG-6219 Program After Phase II Endometriosis Trial Failure

 

Once hailed as a potential game changer, OG-6219 gets the axe after failing in a Phase II endometriosis-related pain trial.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By 

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

More from R&D

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By 

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.